Home > Publications Database > Role of different recombinant PrP substrates in the diagnostic accuracy of the CSF RT-QuIC assay in Creutzfeldt-Jakob disease. > print

001     169154
005     20240311115323.0
024 7 _ |a pmc:PMC10113290
|2 pmc
024 7 _ |a 10.1007/s00441-022-03715-9
|2 doi
024 7 _ |a pmid:36536226
|2 pmid
024 7 _ |a 2192-5917
|2 ISSN
024 7 _ |a 0044-3794
|2 ISSN
024 7 _ |a 0340-0387
|2 ISSN
024 7 _ |a 0302-766X
|2 ISSN
024 7 _ |a 0340-0336
|2 ISSN
024 7 _ |a 0373-031X
|2 ISSN
024 7 _ |a 1432-0878
|2 ISSN
024 7 _ |a altmetric:140489875
|2 altmetric
037 _ _ |a DZNE-2023-00033
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Silva-Correia, Susana
|0 P:(DE-2719)9000766
|b 0
|e First author
|u dzne
245 _ _ |a Role of different recombinant PrP substrates in the diagnostic accuracy of the CSF RT-QuIC assay in Creutzfeldt-Jakob disease.
260 _ _ |a Heidelberg
|c 2023
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1683032302_12619
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The development of the real-time quaking-induced conversion (RT-QuIC), an in vitro protein misfolding amplification assay, was an innovation in the scientific field of protein misfolding diseases. In prion diseases, these types of assays imitate the pathological conversion of the cellular prion protein (PrPC) into a protease-resistant and/or amyloid form of PrP, called PrP resistant (PrPRes). The RT-QuIC is an automatic assay system based on real-time measuring of thioflavin-T (Th-T) incorporation into amyloid fibrils using shaking for disaggregation. It has already been applied in diagnostics, drug pre-screening, and to distinguish between different prion strains. The seeded conversion efficiency and the diagnostic accuracy of the RT-QuIC assay strongly depend on the kind of recombinant PrP (rec PrP) substrate. The DNA sequences of different substrates may originate from different species, such as human, bank vole, and hamster, or from a combination of two species, e.g., hamster-sheep chimera. In routine use, either full-length (FL) or truncated substrates are applied which can accelerate the conversion reaction, e.g., to a more sensitive version of RT-QuIC assay. In the present review, we provide an overview on the different types of PrP substrates (FL and truncated forms), recapitulate the production and purification process of different rec PrP substrates, and discuss the diagnostic value of CSF RT-QuIC in human prion disease diagnostics.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Prions
|2 NLM Chemicals
650 _ 7 |a Creutzfeldt-Jakob disease
|2 Other
650 _ 7 |a Diagnostics
|2 Other
650 _ 7 |a Real-time quaking-induced conversion
|2 Other
650 _ 7 |a Recombinant prion protein substrates
|2 Other
650 _ 7 |a Prion Proteins
|2 NLM Chemicals
650 _ 2 |a Cricetinae
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Sheep
|2 MeSH
650 _ 2 |a Creutzfeldt-Jakob Syndrome: diagnosis
|2 MeSH
650 _ 2 |a Prions: metabolism
|2 MeSH
650 _ 2 |a Prion Proteins: metabolism
|2 MeSH
700 1 _ |a Schmitz, Matthias
|0 P:(DE-2719)9000287
|b 1
|u dzne
700 1 _ |a Fischer, Andre
|0 P:(DE-2719)2000047
|b 2
|u dzne
700 1 _ |a Hermann, Peter
|0 P:(DE-2719)2812183
|b 3
|u dzne
700 1 _ |a Zerr, Inga
|0 P:(DE-2719)2000058
|b 4
|e Last author
|u dzne
773 _ _ |a 10.1007/s00441-022-03715-9
|0 PERI:(DE-600)1458496-7
|n 1
|p 301-306
|t Cell & tissue research
|v 392
|y 2023
|x 2192-5917
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/169154/files/DZNE-2023-00033.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/169154/files/DZNE-2023-00033.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:169154
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9000766
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000287
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2000047
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2812183
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2000058
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2023-08-22
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL TISSUE RES : 2022
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-22
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-12
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2022-11-12
|w ger
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-22
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-22
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-12
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-22
920 1 _ |0 I:(DE-2719)1440011-1
|k AG Zerr
|l Translational Studies and Biomarkers
|x 0
920 1 _ |0 I:(DE-2719)5000037
|k Ext UMG Zerr
|l Ext UMG Zerr
|x 1
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer 1 ; AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 2
920 1 _ |0 I:(DE-2719)1440015
|k Clinical Dementia Research Göttingen
|l Clinical Dementia Research Göttingen
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1440011-1
980 _ _ |a I:(DE-2719)5000037
980 _ _ |a I:(DE-2719)1410002
980 _ _ |a I:(DE-2719)1440015
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21